It moves to the text on this page.
  • Eisai Co., Ltd.(Japanese)
  • Contact Us
  • Site Map
Text Size
Small
Large

Eisai Co., Ltd.

  • About Eisai
    • Message from President
    • Corporate Information
    • Access to Medicines
    • Corporate Governance
    • Japan Business Sites
    • Production and Logistics
    • Marketing
    • News Releases
  • Corporate Mission
    • Corporate Philosophy
    • What is hhc?
    • Compliance
  • Responsibility
    • Message to Stakeholders
    • Eisai's Views on Environmental Issues
    • Environmental and Social Report
    • Social Contribution Activities
    • Potential Suppliers
  • Investors
    • Business Performance Highlights
    • Financial Information
    • Presentations
    • Annual Report
    • IR Calendar
    • Analyst Coverage
    • Investor Kit
    • Share Information
    • Bonds and Ratings
    • IR Site Map
  • Research & development
  • Products
The local navigation starts here.

About Eisai

  • Message from President
  • Corporate Information
  • Access to Medicines
    • Our Approach
    • Our Management
    • Our Activities
  • Corporate Governance
  • Japan Business Sites
  • Production and Logistics
  • Marketing
  • News Releases

Home  >  About Eisai  >  Access to Medicines  >  Our Activities

The text starts here.

Access to Medicines

Our Activities

Our Activities

  • Boosting Research & Development into Neglected Tropical Disease Treatments
    - Eisai Participates in WIPO-Sponsored Global Consortium for Open Innovation Partnerships -
  • Piloting a Public-Private Partnership Business Model in India
  • Education for Alzheimer's Dementia Patients and Their Families
  • Aid in Natural Disasters as Long Term Investment for Affected Areas
  • Eisai Takes Second Clinical Research Fellow From Developing World
  • Status of DEC Provision Program for WHO
  • Working together to treat Chagas Disease with new medicines
  • Working together to develop new and more effective vaccines
  • Working together to fight malaria with new medicines: Exploratory research targeting GWT1
  • Working together to fight malaria with new medicines: Development of an active Toll-like receptor (TLR) 9 antagonist
  • Capacity-building in Cambodia
  • Access to Medicines

Related Links

What is hhc?

human health care

  • Contact Us
  • Site Map

Copyright (C) Eisai Co., Ltd. All Rights Reserved.

Back to Top

  • Privacy Policy
  • Terms of Use
  • Accessibility